AIP

Arteris, Inc. (AIP) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Arteris, Inc. is a leading provider of semiconductor system IP, specifically Networks-on-Chip (NoC) interconnect intellectual property and SoC Integration Automation software. The company operates as a single reporting segment with offices globally, including significant operations in the United States, China, and Europe. As of June 30, 2025, the company had 278 full-time employees.

Key Financial Metrics

Note: Total Investments includes short-term ($21.9M) and long-term ($15.9M) available-for-sale securities.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 13% quarter-over-quarter (QoQ) and 20% year-over-year (YoY) for the six-month period. Licensing, support, and maintenance revenue grew 11% QoQ, while variable royalties surged 44% QoQ.
• Expense Increases: Operating expenses rose 12% QoQ to $23.0 million. Research and Development (R&D) increased 14% and Sales & Marketing (S&M) increased 26%, primarily driven by higher employee-related costs and headcount expansion to support business growth.
• Profitability: While the net loss narrowed slightly on a YTD basis compared to the prior year, the company remains unprofitable with an accumulated deficit of $154.1 million as of June 30, 2025.
• Contract Metrics: Annual Contract Value (ACV) increased to $63.9 million (from $56.1 million in Q2 2024). Confirmed Design Starts rose to 25 in Q2 2025 compared to 21 in Q2 2024.

Outlook, Risks, and Unusual Items

• Guidance & Outlook: Management expects R&D and S&M expenses to continue increasing in absolute terms in the near term. The company believes its cash and investment portfolio ($53.9 million total liquid assets) is sufficient to meet liquidity needs for at least the next 12 months.
• Legislative Impact: On July 4, 2025, the U.S. enacted the "One Big Beautiful Bill Act" (OBBBA), which includes tax reform provisions. The company is currently analyzing the impact, which will be accounted for in Q3 2025.
• Related Party Reversal: The company reversed $0.7 million in accounts receivable and deferred revenue related to a licensing agreement with its equity method investee, Transchip, after determining collection criteria were not met under ASC 606.
• Key Risks:
  • China Exposure: 25% of YTD revenue was derived from China. U.S. export controls and geopolitical tensions pose significant risks to future revenue.
  • Equity Method Investment: Transchip continues to incur losses and relies on raising additional capital; failure to do so could trigger an impairment charge.
  • Customer Concentration: Customer A represented 54% of accounts receivable as of June 30, 2025.

Investor Verification Checklist

• Liquidity Runway: Verify if the $53.9 million in cash and investments is sufficient given the $17.3 million YTD net loss and increasing operating expenses.
• China Revenue Sustainability: Assess the impact of U.S. export controls on the 25% of revenue derived from China and the company's ability to replace this volume.
• Transchip Impairment Risk: Monitor the financial health of the equity method investee (Transchip) for potential future impairment charges.
• Customer Concentration: Evaluate the risk associated with Customer A comprising over half of the accounts receivable balance.
• Stock-Based Compensation: Note that $8.8 million of the YTD operating expenses were non-cash stock-based compensation, which impacts cash burn but not cash flow.